Cargando…

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children

Predictive performance of physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) models of drugs predominantly eliminated through kidney in the pediatric population was evaluated. After optimization using adult clinical data, the verified PBPK models can predict 33 of 34...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, W, Johnson, TN, Xu, H, Cheung, SYA, Bui, KH, Li, J, Al‐Huniti, N, Zhou, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036422/ https://www.ncbi.nlm.nih.gov/pubmed/27566992 http://dx.doi.org/10.1002/psp4.12101

Ejemplares similares

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients
por: Cui, Cheng, et al.
Publicado: (2021)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Reporting guidelines for population pharmacokinetic analyses
por: Dykstra, Kevin, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
por: Janssen, J. M., et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children
por: Jiang, X-L, et al.
Publicado: (2013)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological Considerations
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
por: Nguyen, Jenny‐Hoa, et al.
Publicado: (2022)

Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants
por: Emoto, C, et al.
Publicado: (2015)

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations
por: Yu, Yanke, et al.
Publicado: (2021)

Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases
por: Rasool, Muhammad F., et al.
Publicado: (2021)

Response: Fospropofol: Pharmacokinetics?
por: Bengalorkar, Girish M, et al.
Publicado: (2012)

A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
por: Sjögren, Erik, et al.
Publicado: (2021)

Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment
por: Yoon, Sumin, et al.
Publicado: (2019)

Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity
por: Zhou, L, et al.
Publicado: (2015)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
por: Litjens, Carlijn H. C., et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3
por: Cristea, Sînziana, et al.
Publicado: (2021)

Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions
por: Gao, Liuliu, et al.
Publicado: (2020)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague
por: Nguyen, Dung, et al.
Publicado: (2021)

A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations
por: Talha Zahid, Muhammad, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
por: Ye, Lingling, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
por: Heimbach, Tycho, et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
por: Shen, Chaozhuang, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Modelling of Creatinine‐Drug Interactions in the Chronic Kidney Disease Population
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Physiologic and pharmacokinetic changes in pregnancy
por: Costantine, Maged M.
Publicado: (2014)

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities
por: Dinh, Jean, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6etgo4ebpq52ce6t9hm41rq447